Sanofi NASDAQ: SNY is prioritizing continued growth in Specialty Care while preparing for the loss o

Sanofi (NASDAQ:SNY) reported second-quarter financial results on Thursday. The transcript from the c

Novo Nordisk taps Anthropic AI to speed medicine research, enhance software workflows, and implement

The $925 million (CAD) expansion is adding end-to-end vaccine manufacturing capacity on Canadian soi

Q2 strengthened earnings visibility, with higher guidance and continued Dupixent momentum supporting

Sanofi (SAN:CA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage

Sanofi (NASDAQ: SNY - Get Free Report) and Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF

Sanofi and  Cheplaphar m to create new strategic partnership i n mature medicines

Appointments strengthen rare-disease commercialization planning and strategic partnering capabilitie

This article is part of our monthly series where we highlight five large-cap, relatively safe, divid

Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused bu

MORRISTOWN, N.J. and SCOTTSDALE, Ariz., Sept. 10, 2026 /PRNewswire/ -- Sanofi and USA Pickleball are

Emmy Award-winning actress, entrepreneur and mom Keke Palmer partners with Sanofi to help educate fa

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutini

Sanofi (NASDAQ: SNY - Get Free Report) has earned a consensus recommendation of "Hold" from the fift

Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeli

FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligi

The U.S. Food and Drug Administration approved Moderna, Novavax-Sanofi and ​Pfizer-BioNTech's update

The FDA just approved the company's on-body injector for its blood cancer drug. Analysts see upside

On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Tr

Oz says the MMR vaccine is “not a lethal vaccine” after Trump warned the combined shot could be “qui

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from

Sanofi withdrew its Dupixent application for bullous pemphigoid on June 24, 2026, due to unresolved

Executed IP assignment brings a decade of technology, published research, and pharma-tested behavior

President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from

This article is part of our monthly series where we highlight five large-cap, relatively safe, divid

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the d

Sanofi (SNY) Q2 sales hit $13.48B, beating estimates driven by Dupixent's 37.6% surge. Full deta

Sanofi (NASDAQ:SNY) reported quarterly earnings of $1.21 per share which beat the analyst consensus

Sanofi discontinued amlitelimab for atopic dermatitis after reviewing phase 3 efficacy and safety da

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri

FDA approves Sanofi’s Sarclisa Escena, the first subcutaneous multiple myeloma treatment administere

The US Food and Drug Administration (FDA) has approved subcutaneous (SC) Sarclisa (isatuximab-irfc)

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a plan

Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3

EU opens antitrust probe into Sanofi over claims it disparaged rival flu vaccine Fluad in Germany an

Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chr

Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for s

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its

FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 di

Accelerated approval in children aged eight to 17 years old recently diagnosed with stage 3 T1D to d

Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed